Michiel Tent summarises 6 abstracts from the MS Virtual 2020 and its Encore Event:
- EDSS and age are risk factors for severe COVID-19 in MS patients
Louapre C. MSVIRTUAL2020, Abstract SS02.06. - Brain alterations at onset of first demyelinating event
Collorone S. MSVIRTUAL2020, Abstract LB01.04. - Amantadine, modafinil, and methylphenidate for MS-related fatigue
Nourbakhsh B, et al. MSVIRTUAL2020, Abstract PS13.03. - Masitinib possible new treatment of progressive MS
Vermersch P, et al. MSVIRTUAL2020, Abstract FC04.01. - No new safety signals in ofatumumab open-label data
Cross AH, et al. MSVIRTUAL2020, Abstract P0234. - The MS prodrome
Tremlett H. MSVIRTUAL2020, Abstract PL01.01.
- EDSS and age are risk factors for severe COVID-19 in MS patients
Posted on
Previous Article
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
« Experts recommend three dosing protocols for medical cannabis when treating chronic pain Next Article
Numerous drugs can spawn a broad range of arrhythmias »
Table of Contents: MS Virtual 2020
Featured articles
Online First
Positive results for vagus nerve stimulation in RA
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Positive results for vagus nerve stimulation in RA
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
September 7, 2023
Retinal layer thickness predicts disability accumulation in early RMS
April 19, 2022
AAN 2022 Highlights Podcast
July 30, 2019
New compounds for MS treatment
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com